A new cancer treatment is changing the options for women with recurrent or untreatable uterine cancer. The drug delivers chemotherapy directly to cancer cells and then releases them within them. In a new study, this approach shrank tumor size and slowed disease progression in women whose cancer had returned after standard treatment. The findings point to a potential new treatment option for patients with few remaining treatment options and expand the role of antibody-drug conjugates beyond breast cancer.
A more effective way to deliver treatment
Antibodies are Y-shaped proteins produced by the body to recognize and attach to specific targets, such as a virus or cancer cell. Antibodies have been used as cancer treatments for decades because they can target tumor cells with great precision.
Recently, antibody-drug conjugates have expanded this approach, allowing chemotherapy drugs to be directly attached to these antibodies, turning them into targeted delivery systems. The antibody locates and attaches to a cancer cell. The cell then draws the entire complex in, where the chemotherapy drug is released. Healthy cells are largely left unharmed.
Standard chemotherapy affects the entire body, causing hair loss, mouth ulcers, and a host of other side effects. A new treatment combines two components into a single molecule: an antibody and a chemotherapy drug. This targeted therapy narrows the lesion to where it's most needed. A similar approach is already effective in breast and bladder cancer, suggesting that these treatments may benefit a wider range of patients than originally thought.
Why uterine cancer needs new treatments
Uterine cancer, also known as endometrial cancer, begins in the lining of the uterus. Most women are diagnosed early, and their health improves. However, the situation changes when the cancer returns or spreads. Aggressive forms of endometrial cancer often become difficult to treat after standard chemotherapy and immunotherapy become ineffective.
A new treatment method tested in a recent clinical trial involves transferring multiple chemotherapy drug molecules to a single antibody. This means that each time the antibody binds, a higher dose of the drug enters the cancer cell. Once released, the chemotherapy drug reaches very high concentrations inside the tumor cell.
It's important to note that the chemotherapy drug, once released, can also spread to neighboring cancer cells. This "bystander effect" can allow the treatment to damage neighboring tumor cells even if they themselves don't significantly express the target protein.
These features may help explain why antibody-drug conjugates continue to demonstrate activity in cancers that are no longer responsive to conventional therapy. Rather than simply blocking tumor growth signals, these treatments use antibodies as delivery vehicles for chemotherapy drugs directly to resistant tumors.
What the trial showed
The study involved women whose uterine cancer had recurred or continued to progress despite chemotherapy. Half of them also received immunotherapy. Many had the most aggressive forms of the disease.
Approximately one in four women experienced tumor shrinkage while taking the new drug. In some, tumors disappeared on imaging. More than half of the women in the study either experienced tumor shrinkage or disease stabilization for at least six months. Tumor shrinkage was observed in several aggressive subtypes of uterine cancer, including the two most challenging forms.
The new drug is not without side effects. The most common are decreased blood cell counts, anemia, fatigue, and diarrhea. Some women required treatment interruptions or dose reductions to control these symptoms. Very few women had to discontinue the drug completely, and no new unexpected safety concerns were identified during the study. The pattern of side effects is similar to that observed with other antibody-based drugs used to treat various types of cancer.
A new direction in cancer treatment
The findings reflect a broader trend in oncology toward the use of treatments that combine precise targeting with highly effective drugs. Antibody-drug conjugates (ADCs) are increasingly blurring the line between targeted therapy and chemotherapy, combining both approaches into a single treatment.
Larger trials are currently underway comparing the new drug with standard chemotherapy in women with recurrent uterine cancer. Other studies are combining it with immunotherapy to determine whether this combination can be even more effective.
For aggressive forms of uterine cancer, the value extends beyond the use of a single drug. The study suggests that antibody-drug conjugates may open a new treatment strategy for tumors for which there have historically been few effective treatment options.
This work is part of a series of studies demonstrating how modern antibody strategies can be designed to enhance immune responses, with potential applications across a wide range of diseases and therapeutic approaches.
This article was originally published on Forbes.com.